Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study by Corrie, Pippa G, Dr, Marshall, Andrea, PhD, Dunn, Janet A, Prof, Middleton, Mark R, Prof, Nathan, Paul D, PhD, Gore, Martin, Prof, Davidson, Neville, Prof, Nicholson, Steve, PhD, Kelly, Charles G, FRCR, Marples, Maria, PhD, Danson, Sarah J, PhD, Marshall, Ernest, MD, Houston, Stephen J, MD, Board, Ruth E, PhD, Waterston, Ashita M, PhD, Nobes, Jenny P, FRCR, Harries, Mark, PhD, Kumar, Satish, MD, Young, Gemma, MPhil, Lorigan, Paul, MD

Get full text